Adult/Pediatric Hematology & BMT
Comprehensive Hematology, Stem-Cell Transplant & Cellular Therapy.
Advanced autologous and allogeneic bone marrow transplants and lifelong care—provided by an integrated team
Our service offers comprehensive hematology and cellular therapy care, including autologous and allogeneic stem-cell transplants (matched sibling, matched unrelated, haploidentical, and cord-blood), leukapheresis, cryopreservation, and long-term survivorship clinics. Weekly Hemato-Oncology Board and Cellular-Therapy Committee meetings ensure that treatment plans are based on the latest evidence and tailored to each patient’s needs.
1st
Pediatric BMT program in the UAE0%
mortality rate in full matched related donor BMT60%+
of bone marrow transplants with a >95% success rate< 5%
incidence of post-BMT GVHD complicationsCommon Conditions & Subspecialty Clinics.
- Monitoring of endocrine dysfunction
- Cardiopulmonary assessments
- Neurocognitive evaluations
- Secondary cancer surveillance
- Sickle-cell disease
- Thalassemia major
- Inherited metabolic disorders
- Primary immune deficiencies
- Pediatric leukemias
- Acute and chronic graft-versus-host disease (GVHD)
- Ruxolitinib and other immunomodulators
- Participation in ROCK-inhibitor clinical trials
- Aplastic anemia
- Paroxysmal nocturnal hemoglobinuria (PNH)
- Inherited bone marrow failure syndromes
- Immune thrombocytopenia (ITP)
- Hemolytic anemias
- Leukemia (AML, ALL, CML, etc.)
- Lymphoma (Hodgkin and non-Hodgkin)
- Multiple myeloma
- Myeloproliferative neoplasms (MPNs)
- Acute myeloid leukemia (AML)
- Acute lymphoblastic leukemia (ALL)
- Myelodysplastic syndrome (MDS)
- Aplastic anemia
- Sickle-cell disease
- Thalassemia major
- Relapsed Hodgkin lymphoma
- Non-Hodgkin lymphoma
- Germ-cell tumors
- Multiple myeloma
Procedures & Treatments.
Other Cellular Therapies
Donor Lymphocyte Infusion (DLI)
Haploidentical Transplant
Post-transplant cyclophosphamide GVHD prophylaxis
High-Dose Conditioning Regimens
Myeloablative (Bu/Cy, TBI) and reduced-intensity (Flu/Bu)
Stem-Cell Mobilization
G-CSF ± plerixafor; leukapheresis on Spectra Optia™
Fertility preservation
(sperm & oocyte banking) prior to conditioning
Plasmapheresis for TTP and hyperviscosity
Central-line placement
infection prophylaxis (antiviral, antifungal), CMV monitoring
PET-CT for lymphoma response
whole-body MRI for myeloma lesions
Bone-marrow aspirate/biopsy
with digital morphology and FISH/cytogenetics
NGS-based mutation profiling and chimerism analysis
Flow cytometry minimal-residual-disease(MRD)
panels for leukemia & myeloma
Care Pathway & Coordination.
Referral & Pre-Transplant Work-up
HLA typing, organ-function tests, psychosocial evaluation
Multidisciplinary Transplant Conference
Finalizing conditioning regimen and graft source
Mobilization & Leukapheresis
Stem cells collected or donor arranged; cells cryopreserved
Conditioning & Transplant Day (Day 0)
High-dose chemo ± TBI followed by stem-cell infusion
Engraftment & Acute Phase
Daily labs, GVHD prophylaxis, infection surveillance; expected engraftment day - +14 / +21
Discharge & Long-Term Follow-up
Regular clinic visits (weekly to monthly); survivorship clinic > 2 years post-transplant
Technology & Facilities.
Positive-pressure HEPA rooms
laminar airflow, UV disinfection
AI Early-Warning Sepsis Algorithm
Alerts clinicians 6 hours before clinical deterioration
